Human Monoclonal SARS-COV Antibody
Found to Cross-Neutralize SARS-CoV-2
The findings of a recent study published in the journal nature are relayed succinctly here.
"Here we describe multiple monoclonal antibodies targeting SARS-CoV-2 S identified from memory B cells of an individual who was infected with SARS-CoV in 2003. One antibody, named S309, potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 by engaging the S receptor-binding domain. Using cryo-electron microscopy and binding assays, we show that S309 recognizes a glycan-containing epitope that is conserved within the sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails including S309 along with other antibodies identified here further enhanced SARS-CoV-2 neutralization and may limit the emergence of neutralization-escape mutants."
Pinto, D., Park, Y., Beltramello, M. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature (2020). https://doi.org/10.1038/s41586-020-2349-y
Study Identifies Six Different Antibodies that React with Key Receptors on Covid-19 Virons
A study that aimed to identify antibodies that targeted the ACE-2 receptor that Covid-19 virons utilize to invade host cells has yielded 6 different antibodies with varying degrees of efficacy for SARS-Cov-1 and SARS-CoV-2 strains.
Two of the antibodies show promise in their ability to cross-neutralize the virus.
One of these antibodies known as "7B11" was successful in blocking the binding between the ACE-2 receptor and the receptor binding protein in both variants of the Covid-19 virus. Making it the most potent of prospective antibodies in its direct interference in the ability of the virus to invade host cells and propagate, unlike the others which incite other, indirect neutralizing effects.
Read the full study here: